Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

109.64 -4.90 (-4.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday
Marjorie Taylor Greene spent part of Christmas Eve buying stocks according to recent disclosures. Here's what she bought. 
Via Benzinga
Healthcare And Biotech Stocks Continue Their Slide
Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December. 
Via Talk Markets
Topics ETFs Stocks / Equities
Based on good technical signals, GILEAD SCIENCES INC is potentially setting up for a breakout.
GILEAD SCIENCES INC (NASDAQ:GILD) Reveals Intriguing Technical Aspects. Here's What You Need to Know. 
Via Chartmill
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
(GILD) - Analyzing Gilead Sciences's Short Interest
Via Benzinga
Is GILEAD SCIENCES INC Ready to Break Out of Its Range?
In-Depth Technical Analysis of GILEAD SCIENCES INC. 
Via Chartmill
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
COVID-19 is Not the Same Disease for Everyone
(BPT) - The summer spike in COVID-19 infections, triggered in part by a rise in new variants of the virus, was an unpleasant reminder that COVID-19 is here to stay. As we brace for an anticipated... 
Via Brandpoint
Topics Death
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027. 
Via Benzinga
What Analysts Are Saying About Gilead Sciences Stock
Via Benzinga
Looking At Gilead Sciences's Recent Unusual Options Activity
Via Benzinga
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes. 
Via Benzinga
Price Over Earnings Overview: Gilead Sciences
Via Benzinga
26 Analysts Assess Gilead Sciences: What You Need To Know
Via Benzinga
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety. 
Via Benzinga
Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low
The surge in corporate borrowing is driven by a rally in credit and equity markets, which has pushed borrowing costs to historic lows. 
Via Benzinga
Topics Government
3 Healthcare Stocks For Long-Term Growth And Dividends
Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time. 
Via Talk Markets
3 Spectacular High-Yield Dividend Stocks to Buy in November
High yields aren't a warning indicator with these three stocks. 
Via The Motley Fool
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst upgrades boosting investor confidence. 
Via Benzinga
Topics Earnings
Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?
After Wednesday’s “everything rally” spurred by the election results, investors took a less euphoric approach on Thursday ahead of the Federal Open Market Committee (FOMC) meeting. The Fed is widely... 
Via Benzinga
Topics Economy
Gilead’s Stock Surge: What’s Fueling the Momentum?
Gilead Sciences' financial performance, innovative therapies, and strategic investments position the company for continued growth. 
Via MarketBeat
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales
The company also raised its earnings and sales guidance for the year. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.